Skip to Content

Belviq Approval History

  • FDA approved: Yes (First approved June 27th, 2012)
  • Brand name: Belviq
  • Generic name: lorcaserin
  • Dosage form: Tablets
  • Company: Arena Pharmaceuticals, Inc.
  • Treatment for: Obesity

Belviq (lorcaserin) is a serotonin 2C receptor agonist indicated for chronic weight management in adults who are obese, or overweight and who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.

Development History and FDA Approval Process for Belviq

Jul 19, 2016Approval Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of Belviq XR (lorcaserin HCl) Extended-Release Tablets
Jun 27, 2012Approval FDA Approves Belviq to Treat Some Overweight or Obese Adults
May 10, 2012Lorcaserin Receives Positive Vote From FDA Advisory Committee
Feb  1, 2012Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
Jan 10, 2012FDA Accepts Resubmission of Lorcaserin New Drug Application
Jan  4, 2012Arena Submits Response to FDA Complete Response Letter for Lorcaserin
Dec 22, 2010Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
Oct 25, 2010FDA Issues Complete Response Letter for Lorcaserin New Drug Application
Sep 17, 2010Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
Sep 15, 2010Obesity Expert to Speak to FDA in Support of Treatment Options for Obese Patients
Aug  6, 2010FDA Confirms September 16th Advisory Committee Meeting to Review Lorcaserin for Obesity and Weight Management
Feb 26, 2010Arena Pharmaceuticals Receives PDUFA Date for Lorcaserin NDA
Feb 24, 2010Arena Pharmaceuticals Announces FDA Acceptance of Lorcaserin NDA for Filing
Dec 22, 2009Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.